Analysis of the safety profile of multireceptor peptides
The clinical trial data provides specific frequency information that helps set realistic expectations
They have proven highly effective for managing blood sugar levels and helping with weight loss
None of them constitute clinical monitoring guidance they describe what research-community protocols typically track
Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes For the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1 Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeks 1,2 For the primary endpoint, participants taking retatrutide achieved average A1C reductions of up to 2.0%, using the efficacy estimand
It is not approved for general weight loss, bodybuilding, or anti-aging, and the visceral-fat benefit reverses when the drug is stopped